For decades, the basic compact between the federal government and American universities was straightforward: Washington funds research, universities produce discoveries, and the country benefits. That compact is now unraveling faster than most people in higher education expected. Since taking office, the Trump administration has pursued not one but several simultaneous campaigns against federal research funding: budget cuts, regulatory overhaul, institutional targeting, and agency destabilization. Any one of these would be significant. Together, they amount to a structural transformation of how science gets funded in the United States, with consequences that will take years to fully measure. Start with the money. The White House has proposed cutting the National Science Foundation's budget by 55 percent and the National Institutes of Health's by 5 billion dollars in fiscal year 2027. The NIH plan would consolidate 27 institutes into 22, eliminating the Fogarty International Center, the National Center for Complementary and Integrative Health, and the National Institute on Minority Health and Health Disparities. ARPA H, the biomedical moonshot agency created just four years ago, would lose a third of its funding. Congress rejected nearly identical proposals last year and may do so again. But the proposals are not really about the numbers. They signal what the administration considers expendable, and they force universities into a defensive posture even when the cuts do not materialize. The more consequential move may be regulatory. On May 28, the Office of Management and Budget published a 400 page proposed rule that would insert political appointees into the grant review process at every federal agency. Before any discretionary research grant is issued, an appointee would have to approve it, and would have the authority to suspend or terminate awards deemed inconsistent with administration priorities. The rule bans funding for research on disparate impact, DEI, and gender affirming care, restricts the use of grant money for journal publication and conference travel, and prohibits grants for voter registration or issue advocacy. If finalized, it would take effect in early 2027. Jules Barbati Dajches of the Union of Concerned Scientists put it bluntly: the rule "would replace merit with loyalty to a political leader." Peer review has been the foundation of American scientific funding since Vannevar Bush argued for it in 1945. The OMB rule does not abolish it, but it layers a political filter on top, one that could discourage entire fields of inquiry before a single grant is denied. Researchers working on climate, public health equity, immigration economics, or gender medicine now face a calculation their predecessors never had to make: not just whether their work is scientifically rigorous, but whether it is politically safe. While these policy battles play out in Washington, the agencies themselves are deteriorating from within. NIH Director Jay Bhattacharya assured Congress in March that the agency would distribute all 48.7 billion dollars in fiscal year 2026 funding by the September deadline. But by that point, NIH had issued 74 percent fewer competitive awards than its four year average for the same period. Total funding was 62 percent below prior year levels. The White House had not even released the agency's spending apportionments until nearly halfway through the fiscal year. NIH's workforce has dropped to 17,100, its lowest in two decades, and 16 of its 27 centers lack permanent directors. Bhattacharya, who also serves as acting CDC director, has been interviewing two to four candidates per week for senior roles but has announced no appointments. The agency is not being cut so much as hollowed out. The administration has also demonstrated a willingness to target individual institutions. In April, the NSF froze new grant funding for Duke, Harvard, Princeton, and Yale, flagging their accounts with "Future Awards to Organization on Hold." The four universities had collectively received 218 new NSF grants in 2024; this fiscal year, they managed 13 before the freeze, and Duke and Harvard received none afterward. Thirty three proposals were paused for an average of 91 days, against a normal processing time of 10 days. The freeze on Duke, Harvard, and Yale was lifted on May 28, the same day the OMB rule was published, but Princeton remains locked out with no explanation and no timeline. Harvard had already faced termination of 75 percent of its NSF grants last year before reaching a settlement. The message to university administrators is clear: compliance is expected, and the terms can change without notice. The aggregate effect of all this is visible in the lives of working scientists. A survey of nearly 1,000 NIH funded researchers, conducted by STAT News in early 2026, found that 28 percent had laid off laboratory personnel, 42 percent had canceled planned research projects, and 67 percent had advised their students to pursue careers outside academia. Among junior tenure track faculty, 81 percent said the disruptions threaten their ability to earn tenure. UCLA's Center for Behavioral and Addiction Medicine lost 40 percent of its staff. A diabetes prevention trial in Puerto Rico lost patients. One researcher took a 95 percent pay cut rather than fire the people in her lab. These numbers do not capture the quieter departures. Fourteen percent of survey respondents had turned down international candidates because of visa complications. Thirteen percent had lost lab members to institutions in other countries. The administration's expanded travel bans, mandatory social media disclosures, extended processing delays, and a new 100,000 dollar H 1B fee have made the United States measurably less attractive to the global scientific workforce. This year's Match Day produced the lowest five year rate of international medical graduates securing U.S. residencies. A professor at the University of Alabama at Birmingham observed that top talent is increasingly looking to Europe and Asia, where visa processes are more predictable and research funding is less volatile. What makes the current moment different from previous fights over research budgets is the simultaneity. Past administrations proposed cuts; Congress restored them. The system absorbed the shock because the underlying infrastructure, peer review, agency independence, predictable timelines, welcoming immigration policy, remained intact. The Trump administration is pressuring all of these at once. The budget proposals force universities to lobby. The OMB rule threatens the review process itself. The institutional freezes demonstrate that compliance is no protection. The staffing collapse at NIH means that even appropriated money does not reach researchers on time. And the immigration changes ensure that the human capital America has spent decades attracting begins to look elsewhere. Congress has been the primary check so far, rejecting the deepest cuts and maintaining near flat funding for major agencies. But congressional intervention is reactive and annual. It cannot restore a lab that has already downsized, rehire a postdoc who has moved to Zurich, or undo the chilling effect of a political review regime on a generation of graduate students choosing their research topics. The Federation of American Societies for Experimental Biology has called for multi year funding commitments. The Association of American Universities has described the budget proposals as "a direct assault on the nation's biomedical research enterprise." These are not alarmist statements from fringe groups. They are the measured language of organizations that have worked with administrations of both parties for decades. The federal government currently supports over 300,000 researchers across more than 2,500 institutions. NIH alone generates an estimated 70 billion dollars in annual economic activity. The research enterprise is not just an academic concern; it is infrastructure, in the same way that highways and broadband are infrastructure. The difference is that scientific capacity, once lost, is exceptionally difficult to rebuild. Equipment can be purchased, but trained researchers cannot be restocked from a warehouse. A generation of students who watched their advisors get defunded will make career choices accordingly, and those choices compound over decades. Whether this transformation is intentional strategy or the emergent result of competing political impulses is, at this point, less important than the outcome. American science is being reorganized around new principles, political alignment, institutional compliance, and short term cost reduction, and the people who do the actual work are already adapting, not by fighting, but by leaving.